Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.30 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17567261 | 0.75 | RNPEP (0.37) | RNPEPSLC7A5KISS1RCACNA2D1CACNB3 | |
| SCHEMBL8462357 | 0.75 | RNPEP (0.37) | RNPEPSLC7A5KISS1RCACNA2D1CACNB3 | |
| SCHEMBL1778121 | 0.75 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL25939108 | 0.75 | RNPEP (0.37) | RNPEPSLC7A5KISS1RCACNA2D1CACNB3 | |
| SCHEMBL11009629 | 0.73 | — | — | |
| SCHEMBL17789270 | 0.73 | RNPEP (0.36) | RNPEPSLC7A5KISS1RCACNA2D1CACNB3 | |
| SCHEMBL25327561 | 0.72 | — | — | |
| SCHEMBL489804 | 0.72 | — | — | |
| SCHEMBL2637647 | 0.72 | — | — | |
| SCHEMBL9026180 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2024-06-27 | — | — | US | disclosed |
| WO-2024112894-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208961-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | RNPEP 1441/4885SLC7A5 3239/4885KISS1R 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.